Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer

Phase 4 Completed 33 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This study is designed to investigate the safety and efficacy of the combination of imatinib and vinorelbine in patients with advanced, anthracycline resistant breast cancer

Timeline

Start: 2006-06
Primary completion: 2012-07
Completion: 2012-07

Publications

Results Maass N, Schem C, Bauerschlag DO, Tiemann K, Schaefer FW, Hanson S, Muth M, Baier M, Weigel MT, Wenners AS, Alkatout I, Bauer M, Jonat W, Mundhenke C. Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer. Oncology. 2014;87(5):300-10. doi: 10.1159/000365553. Epub 2014 Aug 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	400 mg	Oral
Subject	Vinorelbine	Small molecule	10 mg/m2	Intravenous
Subject	Vinorelbine	Small molecule	15 mg/m2	Intravenous
Subject	Vinorelbine	Small molecule	20 mg/m2	Intravenous
Subject	Vinorelbine	Small molecule	25 mg/m2	Intravenous

Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer

Summary

Timeline

Publications

Drugs

Indications